Literature DB >> 15840005

Endothelial cell dysfunction: the syndrome in making.

Edmond O'Riordan1, Jun Chen, Sergey V Brodsky, Iva Smirnova, Hong Li, Michael S Goligorsky.   

Abstract

Endothelial cell dysfunction is emerging as the ultimate culprit for diverse cardiovascular diseases and cardiovascular complications in patients with chronic renal diseases, yet the definition of this new syndrome, its pathophysiology and therapy remain poorly defined. Here, we summarize some molecular mechanisms leading from hyperhomocysteinemia, elevated asymmetric dimethylarginine (ADMA) and advanced glycation end products (AGEs)-modified proteins to atherogenic endothelial phenotype and offer a model of endothelial dysfunction based on the interconnectedness of diverse functions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15840005     DOI: 10.1111/j.1523-1755.2005.00256.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

1.  Endothelial health and diversity in the kidney.

Authors:  Mark S Segal; Chris Baylis; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2006-02       Impact factor: 10.121

Review 2.  Endoplasmic Reticulum Stress, a Driver or an Innocent Bystander in Endothelial Dysfunction Associated with Hypertension?

Authors:  Robyn Cunard
Journal:  Curr Hypertens Rep       Date:  2017-08       Impact factor: 5.369

3.  Adjunctive mesenchymal stem/stromal cells augment microvascular function in poststenotic kidneys treated with low-energy shockwave therapy.

Authors:  Xiao-Jun Chen; Xin Zhang; Kai Jiang; James D Krier; Xiangyang Zhu; Sabena Conley; Amir Lerman; Lilach O Lerman
Journal:  J Cell Physiol       Date:  2020-05-19       Impact factor: 6.384

4.  (-)-epicatechin activation of endothelial cell endothelial nitric oxide synthase, nitric oxide, and related signaling pathways.

Authors:  Israel Ramirez-Sanchez; Lisandro Maya; Guillermo Ceballos; Francisco Villarreal
Journal:  Hypertension       Date:  2010-04-19       Impact factor: 10.190

5.  Endothelial Dysfunction in the Context of Blood-Brain Barrier Modeling.

Authors:  A G Kutikhin; D K Shishkova; E A Velikanova; M Yu Sinitsky; A V Sinitskaya; V E Markova
Journal:  J Evol Biochem Physiol       Date:  2022-06-29       Impact factor: 1.621

Review 6.  MicroRNAs in endothelial cell homeostasis and vascular disease.

Authors:  Carlos Fernández-Hernando; Yajaira Suárez
Journal:  Curr Opin Hematol       Date:  2018-05       Impact factor: 3.284

Review 7.  MicroRNAs as pharmacological targets in endothelial cell function and dysfunction.

Authors:  Aránzazu Chamorro-Jorganes; Elisa Araldi; Yajaira Suárez
Journal:  Pharmacol Res       Date:  2013-04-18       Impact factor: 7.658

8.  Increased type IIA secretory phospholipase A(2) expression contributes to oxidative stress in end-stage renal disease.

Authors:  Markus van der Giet; Markus Tölle; Domenico Pratico; Volkmar Lufft; Mirjam Schuchardt; Matthias P Hörl; Walter Zidek; Uwe J F Tietge
Journal:  J Mol Med (Berl)       Date:  2009-10-02       Impact factor: 4.599

Review 9.  MicroRNAs as regulators of endothelial cell functions in cardiometabolic diseases.

Authors:  Elisa Araldi; Yajaira Suárez
Journal:  Biochim Biophys Acta       Date:  2016-01-26

10.  Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation.

Authors:  Ellena Linden; Weijing Cai; John C He; Chen Xue; Zhu Li; Jonathan Winston; Helen Vlassara; Jaime Uribarri
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.